Feb 24 (Reuters) - Dechra Pharmaceuticals PLC:
* DECHRA PHARMACEUTICALS PLC - HY OPERATING PROFIT 23.3 MILLION STG VERSUS 17 MILLION STG
* DECHRA PHARMACEUTICALS PLC - DECLARE AN INTERIM DIVIDEND OF 10.29 PENCE PER SHARE
* DECHRA - OUTLOOK FOR FULL YEAR REMAINS IN LINE WITH MANAGEMENT EXPECTATIONS, ALTHOUGH PERFORMANCE IN NORTH AMERICA WILL REMAIN CHALLENGING
* DECHRA HY REVENUE 248.5 MILLION STG VERSUS 231.4 MILLION STG
* DECHRA - ASSESSING POTENTIAL IMPACT ON GROUP OF COVID-19 VIRUS, IF ANY
* DECHRA - HAVE NO DIRECT OR INDIRECT REVENUES IN CHINA AND CO HAS SUFFICIENT INVENTORY OF CHINESE SOURCED MATERIALS TO DEAL WITH NEAR TERM SUPPLY
* DECHRA - PROLONGED PERIOD OF INTERRUPTION IN CHINA WOULD LEAD TO CO BEING “OUT OF STOCKS” Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.